No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 212 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... August 6, 2025 Ovarian cancer screening trial did not save lives May 12, 2021 FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax... June 3, 2026 Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective May 10, 2022 Load more HOT NEWS Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and... The (un)usual suspects – how early detection research embraces interdisciplinary science EMA Recommends Extension of Therapeutic Indications for Selpercatinib
